GlaxoSmithKline (NYSE: GSK) reported Q2 EPS of GBP0.47, GBP0.71 worse than the analyst estimate of GBP1.18. Revenue for the quarter came in at GBP7.99 billion versus the consensus estimate of GBP10.58 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.